• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HE Junjin, WANG Jiayi, HAO Jingchao, CHENG Haoran, XU Hanmei. Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(4): 476-480. DOI: 10.11665/j.issn.1000-5048.20150415
Citation: HE Junjin, WANG Jiayi, HAO Jingchao, CHENG Haoran, XU Hanmei. Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(4): 476-480. DOI: 10.11665/j.issn.1000-5048.20150415
shu

Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice

More Information
    Graphical Abstract
    • Abstract
  • mPEG-SC20k-HM-3 is a novel anti-angiogenesis peptide with integrin affinity. To investigate the anti-tumor activities of mPEG-SC20k-HM-3 and oxaliplatin(OXA)combination, a transplanted tumor model of human hepatocellular carcinoma SMMC-7721 in nude mice was established. Jin′s formula to evaluate the combination effect was used. Data suggested that the anti-tumor activities of combined groups were better than those of single drug(P< 0. 05). Inhibition rate of group 8(OXA 7. 5 mg/kg and mPEG-SC20k-HM-3 73. 4 mg/kg)was 84. 6%, which showed remarkable superiority to group 3(OXA 7. 5 mg/kg)and group 4(mPEG-SC20k-HM-3 73. 4 mg/kg). The Q of group 8 was 1. 164(> 1. 15). This combination had synergistic effect. Combination of mPEG-SC20k-HM-3 and oxaliplatin is a method of inhibiting hepatocellular carcinoma.
    • FullText(HTML)
    • References (13)
  • [1]
    Enguita-Germán M,Fortes P.Targeting the insulin-like growth factor pathway in hepatocellular carcinoma[J].World J Hepatol,2014,6(10):716-737.
    [2]
    Morise Z,Kawabe N,Tomishige H,et al. Recent advances in the surgical treatment of hepatocellular carcinoma[J]. World J Gastroenterol,2014,20(39):14381-14392.
    [3]
    Folkman J.Tumorangiogenesis:therapeutic implication[J]. N Engl J Med,1971,285(21):1182-1186.
    [4]
    Dong J,Yao SW,Xu YG.Tumor angiogenesis inhibitors[J]. Prog Chem(化学进展),2010,22(10):1994-2002.
    [5]
    Wang JR,Li J,Lu BB,et al.Efficacy of bevacizumab combined with FOLFIRI in the treatment of refractory metatastic colorectal cancer[J].Mod Oncol(现代肿瘤医学),2013,21(3):578-581.
    [6]
    Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer[J]. N Engl J Med,2004,350(23):2335-2342.
    [7]
    Yang CX,Qin SK.Clinical study progression of oxaliplatin for primary hepaticcarcinoma[J].Chin Clin Oncol(临床肿瘤学杂志),2010,15(9):849-855.
    [8]
    Petrelli F,Coinu A,Borgonovo K,et al.Oxaliplatin-based chemotherapy:a new option in advanced hepatocellular carcinoma.A systematic review and pooled analysis[J].J Clin Oncol,2014, 26(8):488-496.
    [9]
    Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis correlation in invasive breast carcinoma[J].N Engl J Med,1991,324(1):1-8.
    [10]
    Bai LM,Huang XF,Xu HM.Investigation of microvessel density and related factors expression for xenografts tumor of HT29 cells in nude mice at different growth stage[J].Chin Pharmacol Bull(中国药理学报),2014,30(6):796-800.
    [11]
    Xv DZ.Evaluation of the combined effect of drugs[J].Prog Physiol Sci(生理科学进展),1992,23(3):248-253.
    [12]
    Jin ZJ,Zhang XW.Equi-probability sum curves and “Q50”[J].J Shanghai Second Hosp(上海第二医院学报),1981,1(1):15-18.
    [13]
    Abdel-Rahman O. Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma[J].Curr Oncol Rep,2014,16(8):394.
    • Related Articles

  • Related Articles

    [1]ZHANG Xue, OUYANG Huizhi, XU Wei, WANG Xiaoying. Effect of celastrol combined medication on the inhibition of HepG2 cell proliferation[J]. Journal of China Pharmaceutical University, 2020, 51(2): 185-192. DOI: 10.11665/j.issn.1000-5048.20200209
    [2]ZHANG Yaodan, JIANG Xinyu, CAO Lanjie, WANG Jie, JIANG Cuihua, ZHAO Mengge, ZHANG Jian, YIN Zhiqi. Gypenoside granules improved lipid metabolism in C57BL/6J mice with hyperlipidemia[J]. Journal of China Pharmaceutical University, 2019, 50(6): 713-720. DOI: 10.11665/j.issn.1000-5048.20190612
    [3]SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
    [4]JIA Chengshu, WANG Junwei, LI Hui, ZHU Qihua, GE Yiran, XU Yungen. Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2017, 48(5): 523-528. DOI: 10.11665/j.issn.1000-5048.20170503
    [5]CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211
    [6]WANG Yuhao, ZHANG Xue, ZHOU Xiaoting, HE Hua, LIU Xiaoquan. Pharmacokinetic interaction between sunitinib and ramipril in rats[J]. Journal of China Pharmaceutical University, 2017, 48(1): 60-65. DOI: 10.11665/j.issn.1000-5048.20170109
    [7]HUANG Feifei, WANG Lei, XU Qinghua, WU Ying, WANG Fangtong. MRI detection method for human gastric cancer orthotopic transplantation model in nude mice[J]. Journal of China Pharmaceutical University, 2016, 47(5): 625-628. DOI: 10.11665/j.issn.1000-5048.20160521
    [8]JIANG Yuqiu, TANG Qiaofei, ZHANG Shuang, YAN Zhiyong. Combined effects of gallic acid and ciprofloxacin on the murine chronic rhinosinusitis model in mice[J]. Journal of China Pharmaceutical University, 2015, 46(5): 600-604. DOI: 10.11665/j.issn.1000-5048.20150514
    [9]WU Keqin. Antitumor activity and mechanism of saikosaponin D combined with oxaliplatin on A549 cells-bearing nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(3): 355-358. DOI: 10.11665/j.issn.1000-5048.20150316
    [10]Prevention of Peripheral Neuropathy in Streptozotocin Diabetic Rats by Methylcobalamin, Gliclazide and Combined Application of Both[J]. Journal of China Pharmaceutical University, 2003, (2): 71-75.

Catalog

    Get Citation
    PDF
    XML
    Article views (1400) PDF downloads (1948) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：435038

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return